
|Videos|September 13, 2022
Gregory Warren Discusses Measuring Value and Scaling Up Value-Based Contracting
Author(s)Laura Joszt, MA, Peter Wehrwein
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Advertisement
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Warren was the keynote speaker on day 2 of the 2022 PBMI Annual National Conference in Orlando, Florida.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients
2
Zepbound linked to lower healthcare costs in older adults with obesity
3
FDA approves brepocitinib for rare skin disease
4
Employer health care costs projected to rise 9.5% in 2027, report finds
5













